Company Filing History:
Years Active: 2004-2005
Title: **Guey-Chuen Perng: Innovating Cancer Treatments with HSV-1-Derived Vectors**
Introduction
Guey-Chuen Perng is a noteworthy inventor based in Alhambra, California, recognized for her contributions to biomedicine. With a focus on the herpes simplex virus type 1 (HSV-1), her innovative work aims to offer selective treatments for malignant cells, reflecting her commitment to advancing cancer therapies.
Latest Patents
Guey-Chuen Perng holds two significant patents. Her latest patent details the development of an HSV-1-derived vector designed for selectively inhibiting malignant cells and expressing desired traits in both malignant and non-malignant mammalian cells. This innovative patent outlines vectors that are non-neurovirulent and engineered to remain inactive in latency. Central to this invention is a method that delivers these vectors to malignant cells, potentially transforming treatments for brain tumors and other malignancies. Furthermore, the patent describes applications for kits that facilitate the expression of specific proteins within mammalian cells, providing tools for enhanced cancer therapies.
Career Highlights
Guey-Chuen Perng’s professional journey is marked by her association with Cedars-Sinai Medical Center, where she collaborates with top-tier researchers and contributes to significant advancements in medical science. Her work emphasizes the intersection of virology and oncology, paving the way for innovative treatments that leverage viral vectors to combat cancer.
Collaborations
Throughout her career, Guey-Chuen has collaborated with distinguished colleagues such as Steven L. Wechsler and Anthony B. Nesburn. These partnerships reflect her commitment to interdisciplinary research and the continuous pursuit of improving medical outcomes through innovative strategies.
Conclusion
Guey-Chuen Perng stands out as a pioneering inventor in the realm of cancer research, utilizing HSV-1-derived vectors to contribute groundbreaking methods for selectively targeting malignant cells. Her patents are indicative of her dedication to harnessing innovative technologies for medical advancement, potentially leading to more effective cancer treatments in the future.